← Guides & information
US EDITION · CHECKED SEPTEMBER 17, 2026
Medication names: what you are comparing
A practical reference to names and approval distinctions—not a treatment selector.
| Name | Ingredient | Context |
|---|---|---|
| Wegovy injection / pill | Semaglutide | Weight-management approvals; formulation, age and indication differ. Check the current label. |
| Zepbound | Tirzepatide | Weight-management product; distinct brand and indications from Mounjaro. |
| Foundayo | Orforglipron | Oral weight-management medicine approved in April 2026 for eligible adults. |
| Saxenda | Liraglutide | Weight-management product; different brand from Victoza. |
| Contrave | Naltrexone / bupropion | Combination weight-management product. |
| Qsymia | Phentermine / topiramate | Combination weight-management product; controlled-drug and pregnancy precautions apply. |
| Xenical / Alli | Orlistat | Prescription and lower-dose over-the-counter versions differ. |
| Phentermine | Phentermine | Approved for short-term use; do not assume long-term prescribing is on-label. |
| Ozempic / Mounjaro / metformin | Various | Diabetes treatments are not interchangeable with weight-management approvals. Any off-label use is a clinician decision. |
| Compounded products | Product-specific | Not FDA-approved. Do not label them generic Wegovy or generic Zepbound. |
This is not an exhaustive medicine list or prescribing guide. Rare-condition treatments, pediatric eligibility and detailed risks require specialist information. A listed medicine is not offered by every provider.
Drugs@FDA: current product labels · FDA Foundayo approval · NIDDK overview
Safety information belongs in the decision
These medicines have contraindications, interactions and potentially serious adverse effects. Read the current medication guide with your clinician; an attractive price does not establish suitability. Do not use our tables to change treatment or dosing.